Search Results for: DST

38 interactions involving DST - dystonin found:

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
Novel BMP1 bone morphogenetic protein 1
  • Degradation of the extracellular matrix
  • Degradation of the extracellular matrix
  • Collagen biosynthesis and modifying enzymes
  • Anchoring fibril formation
  • Crosslinking of collagen fibrils
ABI1 abl interactor 1
  • Regulation of actin dynamics for phagocytic cup formation
  • Regulation of actin dynamics for phagocytic cup formation
  • VEGFA-VEGFR2 Pathway
  • RHO GTPases Activate WASPs and WAVEs
  • RHO GTPases Activate WASPs and WAVEs
  • FCGR3A-mediated phagocytosis
  • FCGR3A-mediated phagocytosis
ANKRD1 ankyrin repeat domain 1
  • PPARA activates gene expression
APC APC regulator of WNT signaling pathway
  • Apoptotic cleavage of cellular proteins
  • Degradation of beta-catenin by the destruction complex
  • Beta-catenin phosphorylation cascade
  • Deactivation of the beta-catenin transactivating complex
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • Signaling by GSK3beta mutants
  • S33 mutants of beta-catenin aren't phosphorylated
  • S37 mutants of beta-catenin aren't phosphorylated
  • S45 mutants of beta-catenin aren't phosphorylated
  • T41 mutants of beta-catenin aren't phosphorylated
  • APC truncation mutants are not K63 polyubiquitinated
  • APC truncation mutants have impaired AXIN binding
  • AXIN missense mutants destabilize the destruction complex
  • Truncations of AMER1 destabilize the destruction complex
  • Ovarian tumor domain proteases
  • Familial adenomatous polyposis
  • Esophageal cancer
  • Gastric cancer
  • Cancer of the anal canal
  • Gallbladder cancer
C1QTNF9 C1q and TNF related 9
CALM1 calmodulin 1
  • CaMK IV-mediated phosphorylation of CREB
  • CaMK IV-mediated phosphorylation of CREB
  • Calmodulin induced events
  • Cam-PDE 1 activation
  • CaM pathway
  • Platelet degranulation
  • Translocation of SLC2A4 (GLUT4) to the plasma membrane
  • Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
  • PKA activation
  • DARPP-32 events
  • Synthesis of IP3 and IP4 in the cytosol
  • Calcineurin activates NFAT
  • Calcineurin activates NFAT
  • eNOS activation
  • Transcriptional activation of mitochondrial biogenesis
  • Inactivation, recovery and regulation of the phototransduction cascade
  • Inactivation, recovery and regulation of the phototransduction cascade
  • Stimuli-sensing channels
  • FCERI mediated Ca+2 mobilization
  • FCERI mediated Ca+2 mobilization
  • Ca2+ pathway
  • Reduction of cytosolic Ca++ levels
  • Sodium/Calcium exchangers
  • Unblocking of NMDA receptors, glutamate binding and activation
  • CREB1 phosphorylation through the activation of Adenylate Cyclase
  • CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde
  • CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde
  • Ras activation upon Ca2+ influx through NMDA receptor
  • Smooth Muscle Contraction
  • Smooth Muscle Contraction
  • Activation of Ca-permeable Kainate Receptor
  • Uptake and function of anthrax toxins
  • VEGFR2 mediated vascular permeability
  • VEGFR2 mediated cell proliferation
  • Phase 0 - rapid depolarisation
  • Ion homeostasis
  • CLEC7A (Dectin-1) induces NFAT activation
  • CLEC7A (Dectin-1) induces NFAT activation
  • RHO GTPases activate IQGAPs
  • RHO GTPases activate PAKs
  • RHO GTPases activate PAKs
  • RAF activation
  • RAF/MAP kinase cascade
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by BRAF and RAF fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • Glycogen breakdown (glycogenolysis)
  • Glycogen breakdown (glycogenolysis)
  • Protein methylation
  • Extra-nuclear estrogen signaling
  • Loss of phosphorylation of MECP2 at T308
  • Regulation of MECP2 expression and activity
  • Ion transport by P-type ATPases
  • Negative regulation of NMDA receptor-mediated neuronal transmission
  • Activation of RAC1 downstream of NMDARs
  • Activation of RAC1 downstream of NMDARs
  • Activation of AMPK downstream of NMDARs
  • Long-term potentiation
  • Long-term potentiation
  • RAS processing
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
  • FCGR3A-mediated IL10 synthesis
  • FCGR3A-mediated IL10 synthesis
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Chlorpromazine
  • Cinchocaine
  • Nicardipine
  • Fluphenazine
  • Isoflurane
  • Trifluoperazine
  • Loperamide
  • Perphenazine
  • Phenoxybenzamine
  • Felodipine
  • Melatonin
  • Promethazine
  • Pimozide
  • Nifedipine
  • Bepridil
  • Calcium
  • Aprindine
  • Deacetoxyvinzolidine
  • tert-butanol
  • Trimethyllysine
  • N-(6-Aminohexyl)-5-Chloro-1-Naphthalenesulfonamide
  • Prenylamine
  • Flunarizine
  • (3Z)-N,N-DIMETHYL-2-OXO-3-(4,5,6,7-TETRAHYDRO-1H-INDOL-2-YLMETHYLIDENE)-2,3-DIHYDRO-1H-INDOLE-5-SULFONAMIDE
  • Myristic acid
  • Calcium citrate
  • Calcium citrate
  • Calcium citrate
  • Calcium Phosphate
  • Calcium Phosphate
  • Calcium Phosphate
  • Calcium levulinate
  • Calcium phosphate dihydrate
  • Calcium phosphate dihydrate
  • Calcium phosphate dihydrate
CDC5L cell division cycle 5 like
  • mRNA Splicing - Major Pathway
CELSR3 cadherin EGF LAG seven-pass G-type receptor 3
CEP63 centrosomal protein 63
  • Regulation of PLK1 Activity at G2/M Transition
  • Loss of Nlp from mitotic centrosomes
  • Recruitment of mitotic centrosome proteins and complexes
  • Loss of proteins required for interphase microtubule organization from the centrosome
  • Recruitment of NuMA to mitotic centrosomes
  • Anchoring of the basal body to the plasma membrane
  • AURKA Activation by TPX2
CLIP4 CAP-Gly domain containing linker protein family member 4
COL17A1 collagen type XVII alpha 1 chain
  • Collagen degradation
  • Collagen biosynthesis and modifying enzymes
  • Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
  • Assembly of collagen fibrils and other multimeric structures
  • Type I hemidesmosome assembly
  • Collagen chain trimerization
  • Epidermolysis bullosa, junctional, including: Epidermolysis bullosa, junctional, Herlitz type (JEB-H); Epidermolysis bullosa, junctional, non-Herlitz type (JEB-nH); Epidermolysis bullosa, junctional, with pyloric atresia (JEB-PA)
DCTN1 dynactin subunit 1
  • MHC class II antigen presentation
  • HSP90 chaperone cycle for steroid hormone receptors (SHR)
  • XBP1(S) activates chaperone genes
  • COPI-mediated anterograde transport
  • COPI-independent Golgi-to-ER retrograde traffic
  • Amyotrophic lateral sclerosis (ALS); Lou Gehrig's disease
  • Perry syndrome
  • Distal hereditary motor neuropathies (dHMN)
DISC1 DISC1 scaffold protein
DTNBP1 dystrobrevin binding protein 1
  • Golgi Associated Vesicle Biogenesis
  • Hermansky-Pudlak syndrome (HPS)
ECPAS Ecm29 proteasome adaptor and scaffold
ERBB2 erb-b2 receptor tyrosine kinase 2
  • Signaling by ERBB2
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • PLCG1 events in ERBB2 signaling
  • PIP3 activates AKT signaling
  • GRB7 events in ERBB2 signaling
  • Downregulation of ERBB2:ERBB3 signaling
  • GRB2 events in ERBB2 signaling
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Sema4D induced cell migration and growth-cone collapse
  • RAF/MAP kinase cascade
  • ERBB2 Regulates Cell Motility
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • ERBB2 Activates PTK6 Signaling
  • Downregulation of ERBB2 signaling
  • TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
  • Constitutive Signaling by Overexpressed ERBB2
  • Drug-mediated inhibition of ERBB2 signaling
  • Signaling by ERBB2 KD Mutants
  • Resistance of ERBB2 KD mutants to trastuzumab
  • Resistance of ERBB2 KD mutants to sapitinib
  • Resistance of ERBB2 KD mutants to tesevatinib
  • Resistance of ERBB2 KD mutants to neratinib
  • Resistance of ERBB2 KD mutants to osimertinib
  • Resistance of ERBB2 KD mutants to afatinib
  • Resistance of ERBB2 KD mutants to AEE788
  • Resistance of ERBB2 KD mutants to lapatinib
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Drug resistance in ERBB2 TMD/JMD mutants
  • Trastuzumab
  • Lapatinib
  • IGN311
  • Trastuzumab emtansine
  • Varlitinib
  • AV-412
  • Pertuzumab
  • Afatinib
  • Tucatinib
  • Tesevatinib
  • Fostamatinib
  • Brigatinib
  • Margetuximab
  • Zanubrutinib
  • Choriocarcinoma
  • Pancreatic cancer
  • Gastric cancer
  • Bladder cancer
  • Endometrial Cancer
  • Ovarian cancer
  • Cholangiocarcinoma
  • Breast cancer
  • Cervical cancer
ERBIN erbb2 interacting protein
  • Signaling by ERBB2
  • Downregulation of ERBB2 signaling
  • Constitutive Signaling by Overexpressed ERBB2
  • Drug-mediated inhibition of ERBB2 signaling
  • Signaling by ERBB2 KD Mutants
  • Resistance of ERBB2 KD mutants to trastuzumab
  • Resistance of ERBB2 KD mutants to sapitinib
  • Resistance of ERBB2 KD mutants to tesevatinib
  • Resistance of ERBB2 KD mutants to neratinib
  • Resistance of ERBB2 KD mutants to osimertinib
  • Resistance of ERBB2 KD mutants to afatinib
  • Resistance of ERBB2 KD mutants to AEE788
  • Resistance of ERBB2 KD mutants to lapatinib
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Drug resistance in ERBB2 TMD/JMD mutants
EXOC1 exocyst complex component 1
  • Translocation of SLC2A4 (GLUT4) to the plasma membrane
  • Insulin processing
  • VxPx cargo-targeting to cilium
ITGB4 integrin subunit beta 4
  • Assembly of collagen fibrils and other multimeric structures
  • Laminin interactions
  • Syndecan interactions
  • Type I hemidesmosome assembly
  • R1295
  • Epidermolysis bullosa, junctional, including: Epidermolysis bullosa, junctional, Herlitz type (JEB-H); Epidermolysis bullosa, junctional, non-Herlitz type (JEB-nH); Epidermolysis bullosa, junctional, with pyloric atresia (JEB-PA)
ITSN2 intersectin 2
  • Cargo recognition for clathrin-mediated endocytosis
  • Clathrin-mediated endocytosis

Page 1 out of 2 pages